Gsa Capital Partners LLP Edgewise Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$9.25 - $19.97 $202,121 - $436,364	21,851 Added 41.49%	74,511 $1.36 Million
Q4 2023 Feb 16, 2024	BUY	$5.51 - $12.1 $47,914 - $105,221	8,696 Added 19.78%	52,660 $576,000
Q3 2023 Nov 15, 2023	BUY	$5.73 - $7.69 $251,913 - $338,083	43,964 New	43,964 $251,000
Q4 2022 Feb 13, 2023	SELL	$7.58 - $11.08 $7,739 - $11,312	-1,021 Reduced 3.73%	26,367 $236,000
Q3 2022 Nov 14, 2022	BUY	$8.08 - $13.58 $81,414 - $136,832	10,076 Added 58.2%	27,388 $269,000
Q2 2022 Aug 09, 2022	BUY	$5.67 - $9.87 $98,159 - $170,869	17,312 New	17,312 $138,000

190

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.77B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.